Top

Published in:

16-05-2024 | Chronic Inflammatory Bowel Disease | Original Article

Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis

Authors: Mengye Wu, Cuiping Li, Xue Zhou, Zhiyong Wu, Jianqi Feng, Xiaolu Guo, Rui Fang, Qinghai Lian, Ming Pan, Xiaorong Lai, Yanwen Peng

Published in: Inflammopharmacology | Issue 4/2024

Abstract

Inflammatory bowel diseases (IBDs) are prevalent and debilitating diseases with limited clinical treatment strategies. Mesenchymal stem cell (MSCs) are pluripotent stem cells with self-renewal capability and multiple immunomodulatory effects, which make them a promising therapeutic approach for IBDs. Thus, optimization of MSCs regimes is crucial for their further clinical application. Wogonin, a flavonoid-like compound with extensive immunomodulatory and adjuvant effects, has been investigated as a potential pretreatment for MSCs in IBD treatment. In this study, we employed the DSS-induced acute colitis mouse model to compare the therapeutic effectiveness of MSCs in pretreated with or without wogonin and further explore the underlying mechanism. Compared to untreated MSCs, MSC_wogonin (pretreated with wogonin) showed greater effectiveness in the treatment of colitis. Further experiments revealed that wogonin treatment activated the AKT signaling pathway, resulting in higher cellular glycolysis. Inhibition of AKT phosphorylation by perifosine not only decreased glycolysis but impaired the therapeutic efficiency of MSC_wogonin. Consistent with these results, qPCR data indicated that wogonin treatment induced the expression of immunomodulatory molecules IL-10, IDO, and AGR1, which were reduced by perifosine. Together, our data demonstrated that wogonin preconditioning strategy further augmented the therapeutic efficacy of MSCs via promoting glycolysis, which should be a promising strategy for optimizing MSCs therapy in IBDs.

Available only for authorised users

Andrzejewska A, Lukomska B, Janowski M (2019) Concise review: mesenchymal stem cells: from roots to boost. Stem Cells (Dayton, Ohio) 37:855–864. https://doi.org/10.1002/stem.3016CrossRefPubMed

Cabalzar-Wondberg D, Turina M, Biedermann L et al (2021) Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn’s disease: a case series. Colorectal Dis Off J Assoc Coloproctol Great Br Irel 23:1444–1450. https://doi.org/10.1111/codi.15587CrossRef

Cheng W, Su J, Hu Y et al (2017) Interleukin-25 primed mesenchymal stem cells achieve better therapeutic effects on dextran sulfate sodium-induced colitis via inhibiting Th17 immune response and inducing T regulatory cell phenotype. Am J Transl Res 9:4149–4160PubMedPubMedCentral

Danese S, Solitano V, Jairath V et al (2022) The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut 71:2380–2387. https://doi.org/10.1136/gutjnl-2022-327025CrossRefPubMed

De Souza HS, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13:13–27. https://doi.org/10.1038/nrgastro.2015.186CrossRefPubMed

Fan H, Zhao G, Liu L et al (2012) Pre-treatment with IL-1beta enhances the efficacy of MSC transplantation in DSS-induced colitis. Cell Mol Immunol 9:81–473. https://doi.org/10.1038/cmi.2012.40CrossRef

Filipescu IE, Leonardi L, Menchetti L et al (2018) Preventive effects of bovine colostrum supplementation in TNBS-induced colitis in mice. PLoS One 13:e0202929. https://doi.org/10.1371/journal.pone.0202929CrossRefPubMedPubMedCentral

Forbes GM, Sturm MJ, Leong RW et al (2014) A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12:64–71. https://doi.org/10.1016/j.cgh.2013.06.021CrossRefPubMed

García-olmo D, García-arranz M, Herreros D et al (2005) A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416–1423. https://doi.org/10.1007/s10350-005-0052-6CrossRefPubMed

Gergely M, Prado E, Deepak P (2022) Management of refractory inflammatory bowel disease. Curr Opin Gastroenterol 38:347–357. https://doi.org/10.1097/MOG.0000000000000849CrossRefPubMed

Gills JJ, Dennis PA (2009) Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11:102–110. https://doi.org/10.1007/s11912-009-0016-4CrossRefPubMedPubMedCentral

Gubser PM, Bantug GR, Razik L et al (2013) Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat Immunol 14:72–1064. https://doi.org/10.1038/ni.2687CrossRef

He J, Zhang N, Zhu Y et al (2021) MSC spheroids-loaded collagen hydrogels simultaneously promote neuronal differentiation and suppress inflammatory reaction through PI3K-Akt signaling pathway. Biomaterials 265:120448. https://doi.org/10.1016/j.biomaterials.2020.120448CrossRefPubMed

Hu X, Xu Q, Wan H et al (2020) PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. Lab Investig J Tech Methods Pathol 100:801–811. https://doi.org/10.1038/s41374-020-0404-9CrossRef

Huldani H, Margiana R, Ahmad F et al (2022) Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells. Int Immunopharmacol 107:108698. https://doi.org/10.1016/j.intimp.2022.108698CrossRefPubMed

Huynh DL, Ngau TH, Nguyen NH et al (2020) Potential therapeutic and pharmacological effects of Wogonin: an updated review. Mol Biol Rep 47:9779–9789. https://doi.org/10.1007/s11033-020-05972-9CrossRefPubMed

Jones N, Vincent EE, Cronin JG et al (2019) Akt and STAT5 mediate naive human CD4+ T-cell early metabolic response to TCR stimulation. Nat Commun 10:2042. https://doi.org/10.1038/s41467-019-10023-4CrossRefPubMedPubMedCentral

Killer MC, Nold P, Henkenius K et al (2017) Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid. Stem Cell Res Ther 8:100. https://doi.org/10.1186/s13287-017-0553-yCrossRefPubMedPubMedCentral

Li M, Zhang YX, Zhang Z et al (2015) Endomicroscopy will track injected mesenchymal stem cells in rat colitis models. Inflamm Bowel Dis 21:77–2068. https://doi.org/10.1097/MIB.0000000000000458CrossRef

Lin H, Li C, Qian S et al (2022) Evaluation of the biological properties of human umbilical cord mesenchymal stem cells in difffferent passages. J Histochem Cytochem 31:341–350. https://doi.org/10.16705/j.cnki.1004-1850.2022.04.003CrossRef

Liu W, Yu M, Xie D et al (2020) Melatonin-stimulated MSC-derived exosomes improve diabetic wound healing through regulating macrophage M1 and M2 polarization by targeting the PTEN/AKT pathway. Stem Cell Res Ther 11:259. https://doi.org/10.1186/s13287-020-01756-xCrossRefPubMedPubMedCentral

Lügering A, Schmidt M, Lügering N et al (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 121(5):1145–1157. https://doi.org/10.1053/gast.2001.28702CrossRefPubMed

Manning BD, Toker A (2017) AKT/PKB signaling: navigating the network. Cell 169:381–405. https://doi.org/10.1016/j.cell.2017.04.001CrossRefPubMedPubMedCentral

Markov A, Thangavelu L, Aravindhan S et al (2021) Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther 12:192. https://doi.org/10.1186/s13287-021-02265-1CrossRefPubMedPubMedCentral

Menk AV, Scharping NE, Moreci RS et al (2018) Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep 22:1509–1521. https://doi.org/10.1016/j.celrep.2018.01.040CrossRefPubMedPubMedCentral

Molendijk I, Bonsing BA, Roelofs H et al (2015) Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology 149:918–27.e6. https://doi.org/10.1053/j.gastro.2015.06.014CrossRefPubMed

Mrahleh MA, Matar S, Jafar H et al (2021) Human Wharton’s Jelly-derived mesenchymal stromal cells primed by tumor necrosis factor-α and interferon-γ modulate the innate and adaptive immune cells of type 1 diabetic patients. Front Immunol 12:732549. https://doi.org/10.3389/fimmu.2021.732549CrossRefPubMedPubMedCentral

Pan T, Sun S, Chen Y et al (2022) Immune effects of PI3K/Akt/HIF-1alpha-regulated glycolysis in polymorphonuclear neutrophils during sepsis. Crit Care (Lond, Engl) 26:29. https://doi.org/10.1186/s13054-022-0389CrossRef

Ren W, Chai M, Jiang M et al (2022) High glucose mediates apoptosis and osteogenesis of MSCs via downregulation of AKT-Sirt1-TWIST. Mol Biol Rep 49:2723–2733. https://doi.org/10.1007/s11033-021-07082-6CrossRefPubMed

Ryu DB, Lim JY, Lee SE et al (2016) Induction of Indoleamine 2,3-dioxygenase by pre-treatment with Poly(I:C) may enhance the efficacy of MSC treatment in DSS-induced colitis. Immune Netw 16:358–365. https://doi.org/10.4110/in.2016.16.6.358CrossRefPubMedPubMedCentral

Strober W, Fuss IJ (2011) Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140(6):1756–1767. https://doi.org/10.1053/j.gastro.2011.02.016CrossRefPubMed

Wang W, Xia T, Yu X (2015) Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-kappaB pathway in vitro. Inflamm Res Off J Eur Histamine Res Soc 64:31–423. https://doi.org/10.1007/s00011-015-0822-0CrossRef

Wu Q, Xie S, Zhu Y et al (2021) Wogonin strengthens the therapeutic effects of mesenchymal stem cells in dss-induced colitis via promoting IL-10 production. Oxid Med Cell Longev 2021:5527935. https://doi.org/10.1155/2021/5527935CrossRefPubMedPubMedCentral

Xu C, Feng C, Huang P et al (2022) TNFalpha and IFNgamma rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property. Stem Cell Res Ther 13:491. https://doi.org/10.1186/s13287-022-03178-3CrossRefPubMedPubMedCentral

Zhang X, Wang S, Ding X et al (2020) Potential methods for improving the efficacy of mesenchymal stem cells in the treatment of inflammatory bowel diseases. Scand J Immunol 92:e12897. https://doi.org/10.1111/sji.12897CrossRefPubMed

Zhou Y, Dou F, Song H et al (2022) Anti-ulcerative effects of wogonin on ulcerative colitis induced by dextran sulfate sodium via Nrf2/TLR4/NF-kappaB signaling pathway in BALB/c mice. Environ Toxicol 37:954–963. https://doi.org/10.1002/tox.23457CrossRefPubMed

Title: Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis
Authors: Mengye Wu
Cuiping Li
Xue Zhou
Zhiyong Wu
Jianqi Feng
Xiaolu Guo
Rui Fang
Qinghai Lian
Ming Pan
Xiaorong Lai
Yanwen Peng
Publication date: 16-05-2024
Publisher: Springer International Publishing
Keyword: Chronic Inflammatory Bowel Disease
Published in: Inflammopharmacology / Issue 4/2024
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-024-01491-2

EASD 2024

Springer Medicine

Wogonin preconditioning of MSCs improved their therapeutic efficiency for colitis through promoting glycolysis

Abstract

EASD 2024

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2024

Surveying haemoperfusion impact on COVID-19 from machine learning using Shapley values

Metformin as adjuvant therapy in obese knee osteoarthritis patients

Exploring the therapeutic effects of sulforaphane: an in-depth review on endoplasmic reticulum stress modulation across different disease contexts

Aegeline attenuates TNBS-induced colitis by suppressing the NFƙB-mediated NLRP3 inflammasome pathway in mice

Ethanol extract of Ziziphus nummularia ameliorates formaldehyde-induced arthritis in rats by regulating oxidative stress biomarkers and haematological profile

Novel antiarthritic mechanisms of Azelaic acid against CFA-induced arthritis in rats by modulating pro- and anti-inflammatory cytokines network